Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
作者信息
Hortobagyi G N, Stemmer S M, Burris H A, Yap Y S, Sonke G S, Paluch-Shimon S, Campone M, Petrakova K, Blackwell K L, Winer E P, Janni W, Verma S, Conte P, Arteaga C L, Cameron D A, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J
出版信息
Ann Oncol. 2019 Nov 1;30(11):1842. doi: 10.1093/annonc/mdz215.
Abstract
摘要
相似文献
1
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.MONALEESA-2的更新结果，这是一项针对激素受体阳性、HER2阴性晚期乳腺癌的III期试验，比较一线使用瑞博西尼联合来曲唑与安慰剂联合来曲唑的疗效。
Ann Oncol. 2019 Nov 1;30(11):1842. doi: 10.1093/annonc/mdz215.
2
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.MONALEESA-2 研究的更新结果，这是一项 III 期临床试验，比较了一线 ribociclib 加 letrozole 与安慰剂加 letrozole 治疗激素受体阳性、HER2 阴性晚期乳腺癌的疗效。
Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.
3
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.MONALEESA-2 随机研究中，新诊断的 HR+、HER2-晚期乳腺癌患者中，接受来曲唑联合瑞波西利与来曲唑单药相比的疗效。
Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21.
4
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.MONALEESA-2 随机试验中，对于激素受体阳性、HER2 阴性的老年乳腺癌患者，来曲唑联合瑞波西利与来曲唑单药治疗的对比。
Breast Cancer Res Treat. 2018 Feb;167(3):659-669. doi: 10.1007/s10549-017-4523-y. Epub 2017 Oct 22.
5
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.来曲唑联合内分泌治疗激素受体阳性、晚期乳腺癌的绝经前妇女（MONALEESA-7）：一项随机 3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.
6
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.来曲唑联合瑞博西利与来曲唑联合帕博西利及来曲唑单药治疗激素受体阳性、人表皮生长因子受体 2 阴性的绝经后晚期或转移性乳腺癌的成本-效果分析：美国支付者视角。
J Manag Care Spec Pharm. 2018 Jun;24(6):514-523. doi: 10.18553/jmcp.2018.24.6.514.
7
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.MONALEESA-2 研究中入组的美国患者使用来曲唑联合瑞博西利的疗效和安全性。
Clin Breast Cancer. 2019 Aug;19(4):268-277.e1. doi: 10.1016/j.clbc.2019.02.007. Epub 2019 Feb 28.
8
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.瑞博西林联合来曲唑治疗晚期乳腺癌的总生存期。
N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663.
9
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.来曲唑联合瑞波西利治疗既往未接受过内分泌治疗的激素受体阳性、HER2 阴性晚期乳腺癌患者：来自 3b 期 CompLEEment-1 试验的亚组安全性分析。
Radiol Oncol. 2022 May 17;56(2):238-247. doi: 10.2478/raon-2022-0020.
10
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.在 MONALEESA-3 期随机对照试验中，对于激素受体阳性、人表皮生长因子受体 2 阴性的绝经后妇女的晚期乳腺癌，来曲唑联合氟维司群治疗：更新的总生存数据。
Ann Oncol. 2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021 Jun 5.
引用本文的文献
1
[Not Available].[无可用内容]
Wien Klin Wochenschr. 2025 Jul 31. doi: 10.1007/s00508-025-02582-y.
2
A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer.一项关于哌柏西利联合内分泌治疗加或不加短期化疗用于HR阳性HER2阴性转移性乳腺癌一线治疗的真实世界研究。
Front Oncol. 2025 Jul 9;15:1512496. doi: 10.3389/fonc.2025.1512496. eCollection 2025.
3
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.NEOLETRIB 试验：来曲唑和瑞博西利在 ER 阳性、HER2 阴性乳腺癌中的新辅助治疗。
Future Oncol. 2024;20(32):2457-2466. doi: 10.1080/14796694.2024.2377531. Epub 2024 Jul 29.
4
Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers.细胞周期蛋白依赖性激酶 2（CDK2）在导管原位癌和早期浸润性乳腺癌中的临床病理意义。
Int J Mol Sci. 2024 May 6;25(9):5053. doi: 10.3390/ijms25095053.
5
The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials.CDK4/6抑制剂用于激素受体阳性/人表皮生长因子受体2阴性乳腺癌的不良事件：随机对照试验荟萃分析的伞状综述
Front Pharmacol. 2024 Jan 15;15:1269922. doi: 10.3389/fphar.2024.1269922. eCollection 2024.
6
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.利用药代动力学和药效学数据研发用于晚期乳腺癌患者的CDK4/6抑制剂瑞博西尼
Clin Pharmacokinet. 2024 Feb;63(2):155-170. doi: 10.1007/s40262-023-01338-z. Epub 2024 Jan 20.
7
Identification of MicroRNAs Associated with Histological Grade in Early-Stage Invasive Breast Cancer.早期浸润性乳腺癌组织学分级相关 microRNAs 的鉴定。
Int J Mol Sci. 2023 Dec 19;25(1):35. doi: 10.3390/ijms25010035.
8
New Concepts in Cardio-Oncology.心血管肿瘤学新概念。
Cancer Treat Res. 2023;188:303-341. doi: 10.1007/978-3-031-33602-7_12.
9
Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies.携带胚系突变的晚期乳腺癌患者中除PARP抑制剂之外的治疗方法：聚焦CDK4/6抑制剂及其他生物疗法的数据综述
Cancers (Basel). 2023 Jun 23;15(13):3305. doi: 10.3390/cancers15133305.
10
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.免疫治疗时代去分化脂肪肉瘤的治疗。
Int J Mol Sci. 2023 May 31;24(11):9571. doi: 10.3390/ijms24119571.
Zotero 插件